Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

The Assessment of Fertility in Men With Spinal Muscular Atrophy (SMA)

NCT ID: NCT06194539Sponsor: Bar-Chama, Natan, M.D.Last updated: 2024-01-08

Summary

This study will aim to assess the fertility status of men with Spinal Muscular Atrophy (SMA) not on disease-modifying therapies. Participants will: 1. Complete online questionnaires that will assess SMA diagnosis and disease burden, medical and surgical history, medication usage, and fertility status and perspectives. 2. Over the 3-month initial study baseline period participants will provide two separate ejaculates for semen analysis and a single determination of sperm quality using DNA fragmentation testing using home collection and subsequent shipment to a central laboratory. 3. Over the initial study baseline period of 3 months study participants will obtain a blood test to determine male reproductive hormone levels. During the 24-month study duration, participants will be requested to undergo a yearly semen analysis and complete online relevant questionnaires.

Detailed description

Study participants will: 1. Complete online questionnaires that will assess SMA diagnosis and disease burden, medical and surgical history, medication usage, and fertility status and perspectives. 2. Over the 3-month initial study baseline period participants will provide two separate ejaculates for semen analysis and a single determination of sperm quality using DNA fragmentation testing using home collection and subsequent shipment to a central laboratory. 3. Over the initial study baseline period of 3 months study participants will obtain a blood test to determine male reproductive hormone levels. During the 24-month study duration, participants will be requested to undergo a yearly semen analysis and complete online relevant questionnaires.

Outcome measures

Primary

  • Semen Volume

    Home collected semen ejaculates will be obtained to measure semen volume (normal \> 1.5ml)

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

  • Sperm Concentration

    Home collected semen ejaculates will be obtained to measure sperm concentration ( normal \> 15 million sperm/ml)

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

  • Sperm Motility

    Home collected semen ejaculates will be obtained to measure sperm motility ( normal \> 39% motile sperm)

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

  • Sperm Morphology

    Home collected semen ejaculates will be obtained to measure sperm morphology (normal \> 4% normal sperm morphology)

    Time frame: Two semen samples will be obtained at the initial 3 month study enrollment and then annually for the duration of the study period of 24 months

  • Sperm DNA Fragmentation Assay

    Home collected semen ejaculates will be obtained to measure sperm DNA fragmentation rate ( normal \< 30% DNA fragmented sperm)

    Time frame: At intial 3 month study enrollment

Secondary

  • Male Reproductive Hormones - Total Testosterone Level

    Time frame: At intial 3 month study enrollment

  • Male Reproductive Hormones - Free Testosterone Level

    Time frame: At intial 3 month study enrollment

  • Male Reproductive Hormones - Follicle Stimulating Hormone

    Time frame: At intial 3 month study enrollment

  • Male Reproductive Hormones - Luteinizing Hormone

    Time frame: At intial 3 month study enrollment

  • Male Reproductive Hormones - Estradiol

    Time frame: At intial 3 month study enrollment

Eligibility criteria

Sex: MaleAge: 18 Years to 50 Years
Inclusion Criteria: * Signed Informed Consent Form (or assent) * Male and age greater than 18 years and less than 50 years of age with a confirmed diagnosis of SMA at the time of signing the Informed Consent Form (or assent) * Currently not on a disease-modifying agent or therapy for SMA * Adequately recovered from any acute illness at the time of screening, and considered clinically well enough to participate in the study. Exclusion Criteria: Men with a prior history of chemotherapy, radiation therapy, prostate or testicular cancer, undescended testicles and use of anabolic steroids or testosterone usage will be excluded

Study locations (1)

Natan Bar-Chama MD

Cresskill, New Jersey, 07626

Recruiting
Natan Bar-Chama, MD · Contact
Assessing the Fertility Status of Men With Spinal Muscular Atrophy (SMA) | Cancerify